LIQUIDIA CORPORATION -

Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

13 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024

06 Mar 2024 06:30:41 By Nasdaq GlobeNewswire

Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress

30 Jan 2024 06:30:11 By Nasdaq GlobeNewswire

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder

25 Jan 2024 06:00:57 By Nasdaq GlobeNewswire

Liquidia Corporation Announces Updates to Operations Leadership

19 Jan 2024 06:30:50 By Nasdaq GlobeNewswire

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

08 Jan 2024 08:22:54 By Nasdaq GlobeNewswire

Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

05 Jan 2024 06:45:01 By Nasdaq GlobeNewswire

Liquidia Corporation Announces $100 Million in New Financings

04 Jan 2024 09:10:24 By Nasdaq GlobeNewswire

Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 06:45:31 By Nasdaq GlobeNewswire

U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)

20 Dec 2023 16:56:00 By Nasdaq GlobeNewswire

Liquidia Announces Pricing of Public Offering of Common Stock

12 Dec 2023 07:13:56 By Nasdaq GlobeNewswire

Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 Nov 2023 06:30:26 By Nasdaq GlobeNewswire

Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023

31 Oct 2023 06:30:15 By Nasdaq GlobeNewswire

FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label

25 Sep 2023 16:09:48 By Nasdaq GlobeNewswire

United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office

06 Sep 2023 16:30:02 By Nasdaq GlobeNewswire

Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update

10 Aug 2023 06:00:58 By Nasdaq GlobeNewswire

Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023

03 Aug 2023 08:17:48 By Nasdaq GlobeNewswire

Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder

27 Jul 2023 06:00:23 By Nasdaq GlobeNewswire

Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America

28 Jun 2023 05:36:17 By Nasdaq GlobeNewswire

Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference

31 May 2023 06:30:39 By Nasdaq GlobeNewswire